Your session is about to expire
← Back to Search
Other
INV-202 for Metabolic Syndrome
Phase 1
Waitlist Available
Research Sponsored by Inversago Pharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
Summary
This trial is testing a new drug called INV-202 to see if it is safe and effective for people with metabolic syndrome. The study will look at how the drug is processed in the body and its effects on conditions like high blood sugar and large waist size over a few weeks.
Eligible Conditions
- Metabolic Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number and Frequency of Adverse Events
Secondary study objectives
Pharmacokinetic profile of INV-202
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: INV-202Experimental Treatment1 Intervention
INV-202 25mg by mouth once daily
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo by mouth once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INV-202
2022
Completed Phase 1
~40
Find a Location
Who is running the clinical trial?
Inversago Pharma Inc.Lead Sponsor
3 Previous Clinical Trials
523 Total Patients Enrolled
1 Trials studying Metabolic Syndrome
243 Patients Enrolled for Metabolic Syndrome
Glenn D Crater, MDStudy DirectorInversago Pharma
1 Previous Clinical Trials
40 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger